Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Glaucoma: Overview01:25

Glaucoma: Overview

538
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
538
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

427
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
427
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

470
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
470

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Monoclonal nephritic factors reveal insights into C3 convertase dynamics and dysregulation.

bioRxiv : the preprint server for biology·2026
Same author

Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy.

The New England journal of medicine·2026
Same author

Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons.

Advances in therapy·2026
Same author

Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN: Phase 3 VALIANT Subgroup Analysis.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Complement 3 Glomerulopathy (C3G) in Native and Posttransplant Kidneys: A Review.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same author

Complement biomarkers during iptacopan treatment - Authors' reply.

Lancet (London, England)·2026
Same journal

New Drugs on the Horizon for Hypertension.

Advances in kidney disease and health·2026
Same journal

Hyperammonemia Physiology and Management: A Nephrology-Centered Review.

Advances in kidney disease and health·2026
Same journal

Hypertension in Advanced Chronic Kidney Disease: Saving the Kidneys or the Heart?

Advances in kidney disease and health·2026
Same journal

Social Determinants of Health and Primary Hypertension in Children and Adolescents: Proposed Solutions Using a Socioecological Model of Health.

Advances in kidney disease and health·2026
Same journal

Blood Pressure Management in the Inpatient and Acute Care Setting.

Advances in kidney disease and health·2026
Same journal

Endocrine Hypertension in Children and Adults: Beyond Primary Aldosteronism.

Advances in kidney disease and health·2026
查看所有相关文章

相关实验视频

Updated: Jun 21, 2025

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.4K

关于C3淋巴细胞病变的最新情况

Benjamin Wooden1, Carla M Nester2, Andrew S Bomback1

  • 1Division of Nephrology, Department of Medicine, Columbia University, New York, NY.

Advances in kidney disease and health
|July 14, 2024
PubMed
概括
此摘要是机器生成的。

C3球囊病 (C3G) 是一种罕见的病,由补体系统调节失调引起. 新的抗补疗法正在开发中,为改善这种疾病的治疗选择提供了希望.

更多相关视频

Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments
08:55

Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments

Published on: April 24, 2020

3.0K
A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
09:26

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

19.4K

相关实验视频

Last Updated: Jun 21, 2025

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.4K
Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments
08:55

Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments

Published on: April 24, 2020

3.0K
A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
09:26

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

19.4K

科学领域:

  • 腎臟病學 (nephrology) 是一種醫學專業.
  • 免疫学 免疫学 免疫学
  • 补充系统生物学 补充系统生物学

背景情况:

  • C3球囊病 (C3G) 是一种罕见的病,其特点是球囊中C3的沉积.
  • 它是由于遗传或获得因素导致的替代补充路径失调造成的.
  • C3G会导致球损伤,导致发性和发性综合征,预后不佳.

研究的目的:

  • 为了提供C3球病的概述.
  • 要总结C3G.目前治疗证据.
  • 详细介绍C3G.正在进行的临床试验.

主要方法:

  • 关于C3球病的现有文献的综述.
  • 对当前治疗策略的分析.
  • 从正在进行的临床试验中汇编数据.

主要成果:

  • 对C3G机制和病变的理解有了显著的进步.
  • 对C3G的治疗选择仍然有限.
  • 几种抗补剂疗法正在临床试验的后期阶段.

结论:

  • 抗补剂疗法在C3G治疗中表现有前途.
  • 预计很快将有针对性的治疗选择.
  • 正在进行的试验对于推进C3G管理至关重要.